To understand the potential utility of MRE in monitoring the effects of anti-VEGF treatment in our GBM model, we performed an in vivo study in which treatment was performed on well-established tumors (day 8 post intracranial tumor cell injection; Group 3, Fig. 1a). The gene discussed is VEGFA; the disease is neoplasm.